Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Metabolic dysfunction-associated steatotic liver disease (MASLD) closely associates with obesity and type 2 diabetes. Lifestyle intervention and bariatric surgery aiming at substantial weight loss are cornerstones of MASLD treatment by improving histological outcomes and reducing risks of comorbidit...

詳細記述

保存先:
書誌詳細
主要な著者: Maximilian Huttasch, Michael Roden, S. Kahl
フォーマット: Artigo
言語:英語
出版事項: 2024
オンライン・アクセス:https://doi.org/10.1016/j.metabol.2024.155937
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!